The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings.
 
Michael Francis Walsh
No Relationships to Disclose
 
Elise Fiala
No Relationships to Disclose
 
Ozge Birsoy
No Relationships to Disclose
 
Tamanna Haque
No Relationships to Disclose
 
Eytan M. Stein
No Relationships to Disclose
 
Neerav Shukla
Consulting or Advisory Role - Illumina
 
Maria Luisa Sulis
No Relationships to Disclose
 
Aaron David Goldberg
No Relationships to Disclose
 
Satshil Rana
No Relationships to Disclose
 
Aliya Khurram
No Relationships to Disclose
 
Angelika Padunan
No Relationships to Disclose
 
Omar Ibrahim Abdel-Wahab
No Relationships to Disclose
 
Ross L. Levine
Leadership - Qiagen
Stock and Other Ownership Interests - Ajax; Anovia; Auron Therapeutics; BAKX Therapeutics; C4 Therapeutics; Epiphanes; Imago Pharma; IsoPlexis; Kurome Therapeutics; Loxo; Mana Therapeutics; Mission Bio; Prelude Therapeutics; Qiagen; Scorpion Therapeutics; Syndax; Zentalis
Honoraria - Amgen; Celgene; Genome Canada; Gilead Sciences; Incyte; Janssen; Lilly; The Mark Foundation For Cancer Research
Consulting or Advisory Role - BMS; Bridge Medicines; Bridge Therapeutics; Bridgebio; C4 Therapeutics; Celgene; Daiichi; Imago Pharma; IsoPlexis; Jubilant Biosys; Loxo; MorphoSys; Novartis; Prelude Therapeutics; Roche; Stelexis Therapeutics; Vida Ventures
Speakers' Bureau - Amgen; Lilly
Research Funding - Celgene; Cure Breast Cancer Foundation; ECOG-ACRIN; Prelude Therapeutics; Roche; The Mark Foundation For Cancer Research
Travel, Accommodations, Expenses - Auron Therapeutics; C4 Therapeutics; Constellation Pharmaceuticals; Genome Canada; Incyte; Qiagen
 
Luis A. Diaz
Leadership - Epitope Diagnostics; Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners
 
Marcel R. M. Van Den Brink
Honoraria - BeiGene (I); Ceramedix; Da Volterra; Forty Seven; Frazier Healthcare Partners; GlaxoSmithKline; Lygenesis; Magenta Therapeutics; Merck; Nektar; Notch Therapeutics; Novartis (I); Pluto Immunotherapeutics; Priothera; Rheos Medicines; Seres Therapeutics; Synthekine (I); WindMIL; WindMIL
Consulting or Advisory Role - Seres Therapeutics
Research Funding - Seres Therapeutics
Patents, Royalties, Other Intellectual Property - Dr. van den Brink receives royalties from Wolters Kluwer, and he has intellectual property Licensing with Seres Therapeutics and Juno Therapeutics
Travel, Accommodations, Expenses - Rheos Medicines
Other Relationship - DKMS
(OPTIONAL) Uncompensated Relationships - Notch Therapeutics; Pluto Immunotherapeutics; Seres therapeutics
 
Marc Ladanyi
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bayer; Merck; Paige.AI
Research Funding - Elevation Oncology (Inst); Merus NV (Inst); Rain Therapeutics
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Maria E. Arcila
Consulting or Advisory Role - AstraZeneca; Axis Medical Education; Bristol-Myers Squibb; Clinical Education Alliance; Janssen; Physicans' Education Resource; RMEI Medical Education; Roche
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Gyroscope (I); Neurogene (I); Optos (I); Outlook Therapeutics (I); Regeneron (I); Regenxbio (I)
 
Diana Mandelker
No Relationships to Disclose